Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System
- 23 August 2023
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 25 (9) , 579-588
Abstract
Background: The advanced hybrid closed-loop (AHCL) algorithm combines automated basal rates and corrections yet requires meal announcement for optimal outcomes. We aimed to compare the performance of the MiniMed™ 780G AHCL algorithm with and without meal announcement. Methods: In a single-arm study involving 14 adults with type 1 diabetes, we evaluated the safety and efficacy of AHCL when meals were not announced. Participants stayed at a supervised environment for 5 days, during which the outcomes of not announcing meals (≤80 g of carbohydrate) were assessed. Next, participants entered a 90-day at-home “unannounced” phase, during which all meals (≤80 g of carbohydrate) were unannounced, followed by a 90-day at-home phase in which all meals were announced. Results: Time in range (TIR 70–180 mg/dL) was lower in the unannounced versus announced periods (67.5% ± 12.5% vs. 77.7% ± 9.5%; P < 0.01, respectively), with more time spent in hyperglycemia range 180–250 mg/dL (22.7% ± 7.7% vs. 15.7% ± 7.2%) and >250 mg/dL (7.9% ± 6.4% vs. 3.6% ± 2.7%), but less time in hypoglycemia range 54–70 mg/dL (1.6% ± 1% vs. 2.8% ± 1.8%) and 250 mg/dL, and up to 20 g of unannounced carbohydrates did not significantly change the TIR 70–180 mg/dL compared with full announcement. Conclusion: The AHCL system is optimized for use with meal announcement. While not announcing meals of ≤80 g carbohydrates appears to be safe, it results in suboptimal postprandial glycemic control, especially with high-carbohydrate meals. Not announcing small meals (≤20 g carbohydrate) does not deteriorate glycemic control. Clinical Trial Registration number: NCT04479826Keywords
This publication has 22 references indexed in Scilit:
- Six months of hybrid closed loop in the real‐world: An evaluation of children and young adults using the 670G systemPediatric Diabetes, 2019
- Increased proportion of time in hybrid closed‐loop “Auto Mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pumpDiabetes, Obesity and Metabolism, 2019
- Long‐term real‐life glycaemic outcomes with a hybrid closed‐loop system compared with sensor‐augmented pump therapy in patients with type 1 diabetesDiabetes, Obesity and Metabolism, 2019
- One Year Clinical Experience of the First Commercial Hybrid Closed-Loop SystemDiabetes Care, 2019
- Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day‐and‐night hybrid closed‐loop use in very young children with type 1 diabetesPediatric Diabetes, 2019
- Real-World Implications of Hybrid Close Loop (Hcl) Insulin Delivery SystemEndocrine Practice, 2019
- Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 DiabetesDiabetes Technology & Therapeutics, 2019
- Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial LaunchDiabetes Technology & Therapeutics, 2018
- Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover StudyDiabetes Technology & Therapeutics, 2016